NeoVax With Nivolumab in Patients With Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy
- Status
- UNKNOWN
- Phase
- PHASE2
Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE1
A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
- Status
- COMPLETED
- Phase
- PHASE2